Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J.
Seymour LW, et al. Among authors: schatzlein a.
Int J Oncol. 2009 Jun;34(6):1629-36. doi: 10.3892/ijo_00000293.
Int J Oncol. 2009.
PMID: 19424581
Clinical Trial.